Dr. Michael Wallin Carringer, MD

Dr. Carringer practices at University of Tennessee Medical Center in Knoxville, Tennessee.

Dr. Carringer's NPI, 1306039649, was assigned on August 21, 2007. Dr. Carringer holds Tennessee license 46463.

Dr. Carringer's primary practice is University of Tennessee Medical Center, at 1924 Alcoa Hwy, Knoxville, TN 37920 in Knox County. The practice phone is (865) 544-9000.

Dr. Carringer's primary practice is University of Tennessee Medical Center in Knoxville, Tennessee. The medical group on file is UT Internal Medicine - Pellissippi.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carringer practices. Vendor and product names are available with a free account.

Hospitalist is Dr. Carringer's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dr. Carringer is licensed in Tennessee.

CMS data shows 257 Medicare services from Dr. Carringer across 4 procedure codes in 2024, for 103 Medicare patients. Medicare paid $21,394 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 103 Medicare patients who saw Dr. Carringer in 2024. The largest group is 75 to 84, with 37 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.46, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carringer's median patient age at 76, with 27% women.

In 2024, Dr. Carringer wrote 100 Medicare Part D claims for 50 patients. 91% of them were for generic drugs. CMS names the drug for 40 of them, across 3 drugs with 11 or more claims each, at $306 in total drug cost. In 2021, CMS named 60 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Carringer for performance year 2024, reported through an alternative payment model (APM).

CMS Open Payments shows 94 general payments to Dr. Carringer from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $222.